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Abstract
Background: While there is a great deal of research updating methods for estimating renal function, many of these
methods are being developed in either adults with CKD or younger children. Currently, there is limited
understanding of the agreement between the modified new bedside Schwartz estimated glomerular filtration rate
(eGFR) formula and the adult CKD-EPI formula in adolescents and young adults (AYAs) with chronic kidney disease
(CKD) measured longitudinally.
Methods: Longitudinal cohort study of 242 patients (10–30 years) with CKD, followed retrospectively in a single
tertiary centre as they transitioned from the paediatric- to adult-focused settings. The study population came from
a longitudinal cohort of AYAs undergoing healthcare transition at the STARx Program at the University of North
Carolina, in the South-Eastern USA, from 2006 to 2015. We calculated and compared the eGFR using the new
bedside Schwartz formula and the CKD-EPI eGFR. Measurements were repeated for each age in years. Agreement
was tested using Bland & Altman analysis. Subgroup analysis was performed using the following age groups 10–15,
15–20, 20–25 and 25–30 years, glomerular and non-glomerular causes of CKD and height z-score.
Results: Using repeated measures, concordance between the new Schwartz and CKD-EPI eGFR was low at 0.74
(95% C.I. 0.67, 0.79) at the lowest age range of 10–15, 0.78 (95% C.I. 0.71, 0.84) at age 15–20, 0.80 (0.70, 0.87) at ages
20–25, and 0.82 (95% C.I. 0.70, 0.90) at age 25–30. Discordance was worse in males and largest in the 10–15 year-
old age group, and in patients with stunted growth.
Conclusions: The Schwartz and CKD-EPI equations exhibit poor agreement in patients before and during the
transition period with CKD-EPI consistently yielding higher eGFRs, especially in males. Further studies are required to
determine the appropriate age for switching to the CKD-EPI equation after age 18.
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Background
Chronic kidney disease (CKD) is associated with signifi-
cant morbidity in adolescents and young adults (AYAs),
but the true prevalence of CKD in these patients is un-
known [1]. What is known is that AYAs with end-stage
kidney disease (ESKD) - those who need dialysis or a
transplant - are less than 5% of all ESKD patients in the
USA; yet, they have a 10-year survival of 70–85%; [2–4]
CKD is a progressive disease which requires careful moni-
toring of kidney function. The estimated glomerular filtra-
tion rate (eGFR) is the most widely used surrogate marker
of kidney function [5] and is typically calculated based on
endogenous biomarkers such as serum creatinine or cysta-
tin C [6]. In children, the new bedside Schwartz formula
(developed in a USA cohort of children with CKD and
subsequently referred to simply as the new or modified
Schwartz formula) [7] is recommended; whereas in adults,
the CKD-EPI formula based on cystatin C and serum cre-
atinine (developed from large studies from different parts
of the world and differing measured GFR methods) is en-
dorsed through international guidelines [8]. These equa-
tions estimate renal function based upon various factors
that may include: age, sex, height, and ethnicity. Both the
adult and paediatric formulae advocate for the bivariate
combination of cystatin C (measured against the new
international reference materials [9]) and calibrated (iso-
tope dilution mass spectrometry (IDMS) traceable) serum
creatinine [10]. However, most centres use creatinine-
based formulae only. For paediatric CKD patients, the
new Schwartz formula is recommended, whereas the
CKD-EPI formula is recommended by the Kidney Disease
Outcomes Quality Initiative (KDOQI) guidelines for all
adults while the best age cut-off is not well defined.
Most of the adult formulae such as the Cockcroft Gault,
[11] the CKD-EPI formula [12] or the new CKD-EPI
based on beta-trace protein and beta-2-microglobulin [13]
are not suitable for paediatric patients. Selistre [12] advo-
cates for the use of the new Schwartz formula in young
adults, but this recommendation has not yet been vali-
dated. Our objective was to explore the extent of the
agreement between the new Schwartz and the new
CKD-EPI equations in a longitudinal, racially diverse co-
hort of AYAs with CKD. We hypothesized that the equa-
tions would become more similar as patients aged.
Methods
Study design
Descriptive retrospective longitudinal observational co-
hort study.
Setting
Patients were recruited from the University of North
Carolina STARx (Self-management and Transition to
Adult-focused healthcare with Rx = treatment) Program
(recruitment details noted in Ferris et al. 2015) [14–16].
Participants
Patients from the STARx Program were eligible for inclu-
sion in this study if they were prevalent or incident CKD
cases followed annually at either the paediatric- or
adult-focused nephrology clinics. Patients were excluded
if they had spina bifida or muscular dystrophy, condi-
tions that would drastically alter muscle mass. We con-
sented patients and parents to access their electronic
health record (system available since 1984) under a
protocol and using forms approved by the University of
North Carolina at Chapel Hill. The study adhered to the
Declaration of Helsinki. The patients’ longitudinal med-
ical and laboratory information since their first visit to
the medical centre was obtained. For this study, we col-
lected the patients’ basic demographic information (e.g.,
age, sex, and race), serum creatinine, anthropometrics
(e.g., height and weight), and if applicable, dates of trans-
plants and dialysis. Individuals were censored from the
population after their first dialysis or after renal trans-
plant due to potential inaccuracy in creatinine clearance
estimation because of renal replacement therapy or graft
function. Analyses (with the exception of the graphical
population curves) required complete case data on age,
race, sex, gender, and creatinine.
Variables
The primary outcome variable was their eGFR, which
was calculated by the new Schwartz or new CKD-EPI es-
timating equations based upon creatinine, with all re-
quired covariates abstracted from the medical record.
These equations were chosen because cystatin C mea-
surements were rarely, if ever, ordered during the time
period covered by the study. Schwartz eGFRs were cal-
culated using the new Schwartz estimating equation: [7].
eGFR ¼ 0:413 Heightcm
Scrmg
dL
or eGFR ¼ 36:2  Heightcm
Scrumol
L:
CKD-EPI eGFRs were estimated with the 2009 itera-
tions of the CKD-EPI equation: [8]
eGFR ¼ C 
SCrmg
dL
S
 k
 0:993Age   1þ 0:159  African Americanð Þ
Where C = 144 and S = 0.7 if the patient was female
and C = 141 and S = 0.9 if the patient was male. We used
k = − 0.329 if the patient was female with serum creatin-
ine ≤0.7, k = − 1.209 if the patient was female with serum
creatinine > 0.7, k = − 0.411 if the patient was male with
serum creatinine ≤0.9 and k = − 1.209 if the patient was
male with serum creatinine > 0.9. For use with SI units,
S and serum creatinine bounds were replaced with 61.9
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for females and 79.6 for males; while the other coeffi-
cients remained the same.
Measurement
The UNC laboratory measured creatinine using the
OrthoClinical Diagnostics Vitros Creatinine slide. They
used Jaffe’s reaction and switched to an enzymatic
IDMS-traceable assay in May 2008; prior measurements
were corrected by multiplying them by a factor of 0.95.
All heights were measured with a standing stadiometer
at routine clinic visits. Heights were cleaned to remove
implausible values (i.e. > 300 cm) or values that were en-
tered with incorrect units (i.e. a patient going from
100 cm to 254 cm back to 100 cm), and if a particular
creatinine did not have a height associated with the visit,
heights were interpolated as a weighted average of the
previous and next height measurements. Measurements
for each patient within each half-year were averaged to
obtain an overall estimate for that half-year of age.
Quantitative variables
Age was used as a continuous variable. Z-score of height
was also used to divide patients into thirds relative to
the z-score distribution of the overall cohort and allow
assessment of concordance differences based upon rela-
tive stunted growth. Height z-scores were based on the
Centers for Disease Control and Prevention’s growth
charts [17].
Bias
No formal methods were used to correct for systematic
biases. However, patients were enrolled consecutively
during the study period with a response rate of 97% and
lack of time was the sole reason given for
non-enrolment. Thus, the patient sample is representa-
tive of the patients UNC serves in terms of race, sex and
insurance. Given that more than half of the individuals
studied had an eGFR> 60 at study entry, there remains
the possibility that the results could be biased due to
systematic underestimation of the eGFR in that group
using the Schwartz equation. However, bias of the
Schwartz equation in children is greater in children with
low GFR, rather than GFR close to normal [18].
Statistical methods
We used graphical and statistical methods to capture
changes in the extent of disagreement between the new
Schwartz and the CKDEPI eGFR estimations as patients
in our cohort aged. Locally weighted polynomial regres-
sion (LOESS) curves were generated for each measure of
eGFR over time using R packages “ggplot2” [19] and
“ggExtra” [20]. These curves represent the average of the
eGFR from a given equation at each age across the total
population (with each individual representing at most
one data point at a given age). The closer the two lines
are to one another at a given age, the more similar the
overall population estimates generated by the new
Schwartz and CKDEPI are. Similar graphs were con-
structed to compare the new Schwartz and CKDEPI
eGFR estimation in relevant subgroups of interest with
stratification by sex, race, type of chronic kidney disease,
and z-score of height at current age.
Considering that we lack access to true measured GFR
data in this longitudinal data set (i.e. inulin clearance),
statistical disagreement was captured using the concord-
ance correlation coefficient. This method assesses the
extent of agreement for two measures of the same base
quantity more effectively than a t-test or normal correl-
ation coefficient [21]. A variant of this method has been
adapted for use through repeated measurements on indi-
viduals, which allows us to leverage the full breadth of
our longitudinal data set rather than relying on
cross-sectional cuts. This method also allows us to esti-
mate the concordance correlation coefficient across dif-
ferent age periods, assessing changes in our estimate of
the concordance correlation coefficient as patients aged.
We estimated concordance correlation coefficients using
R package “cccrm” [22] and creatinine measurements
from age 10–15, 15–20, 20–25, and 25–30; these age
groups were chosen to make sure early adulthood could
be split into two phases, as well as give one final cat-
egory to assess agreement once individuals were far from
adolescence. We also created a Bland-Altman plot (cre-
ated using R package “BlandAltmanLeh” [23]) for each
age group to visualize information about disagreement;
unfortunately, unlike the concordance correlation coeffi-
cient, these plots cannot integrate and adjust for informa-
tion about repeated measurements. To assess whether this
would dramatically alter results, we created a second set
of supplementary Bland-Altman plots in which individuals
only contributed one dot per age group based upon their
mean values in that age range. To assess whether sub-
group effects might differ, sub-analyses were conducted
across relevant strata of interest, including sex, race (Afri-
can-American vs. not African-American), type of kidney
disease (glomerular vs. not glomerular), and Z-score of
height based upon the CDC’s growth charts [17].
To investigate potential differences in CKD stage
categorization between the equations at age 18 differentially
across height groups, we constructed an additional graph.
Data management and table generation were performed in
both SAS 9.4 for Windows (SAS Institute Cary, North Car-
olina) and R using packages “dplyr” [24] and “xtable [25].”
We used novel methods to estimate the proportions of
the variance in the ratio of the CKD-EPI value to the
new Schwartz value explained by height Z-score, type of
CKD, age, sex, and race. The classical R2 for linear
models measures the proportion of variance explained
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by a set of fixed predictors. Additionally, semi-partial R2
statistics measure the relative explanatory power of one
specific predictor in the set after accounting for the
others. Several analogues of the R2 are available for lin-
ear mixed models (LMMs), which are frequently used to
characterize longitudinal data. Using the “lme4” [26]
package, we fitted a LMM with the ratio of eGFRs mod-
elled as a function of race, sex, age, and height Z-score.
Using the “r2glmm” [27] package, measures of general-
ized explained variance were computed for the model
and each predictor. Generalized explained variance may
be interpreted as the proportion of multi-dimensional
scatter that can be attributed to structural components
(i.e. predictors) of a LMM [28].
Missing data and loss to follow-up
We conducted a complete case analysis; that is, observa-
tions from a patient were only eligible for inclusion in
our assessments if they were not missing data in any of
the variables used to assess their eGFR. Once patients
were lost to follow-up in creatinine measures, they no
longer contributed to our eGFR comparisons.
Results
Participants
We enrolled 292 AYAs from the STARx Program who had
the diagnosis of CKD. We excluded 50 AYAs from the
analysis since they did not receive care at the clinic prior
to their transplant or initiation of dialysis, yielding no us-
able creatinine measurements. No AYAs were identified
with either spina bifida or neuromuscular dystrophy.
Descriptive data
A majority (59%) of these AYAs had glomerular disease, and
slightly less than half (47%) of patients had CKD stages ≥3
based upon an estimate of their renal function using the new
Schwartz and the KDIGO categories [29] at their first re-
corded height. Over half (55%) of patients were male, and
over one-third (38%) were African-American, representative
of the population we serve. The median age at entry into this
cohort was 13.6 years (interquartile range 11.4; 16.3 years)
and the median duration of follow-up was 4.0 years (inter-
quartile range 1.4; 6.3 years); both were not normally distrib-
uted. In general, AYAs had greater than average BMI,
though there was a wide variance and while 26 AYAs had
missing heights at all their visits these patients represented
very little potential follow-up time overall. Otherwise, miss-
ing data for key variables was negligible. For full details of
the descriptive population statistics, see Table 1.
Main results
Figure 1 is the smoothed population eGFR trajectories
for the patients included in the study population across
time. Panel A is the trajectory for the overall population,
while Panel B shows stratified trajectories of men and
women. This figure depicts agreement between equations
improving over time as the trend lines become closer to-
gether with much more improvement in women in men.
Additional file 1 shows additional smoothed population
eGFR trajectories in additional subpopulations.
Figure 2 is a panelled Bland-Altman plot for each of
the four age categories. Additional file 2 contains a pan-
elled Bland-Altman plot removing the potential for re-
peat observations. Both show improvement in
agreement across the age groups. When the analysis
with repeated measures was performed, concordance is
initially low at 0.74 (95% C.I. 0.67, 0.79) at the lowest
age range of 10–15 but trends upwards at 0.78 (95% C.I.
0.71, 0.84) at age 15–20, 0.80 (0.70, 0.87) at ages 20–25,
and 0.82 (95% C.I. 0.70, 0.90) at age 25–30. This trend
across age holds within every stratum. There is a mark-
edly higher concordance in every age range comparing
females to males. Females have a value of 0.82 (95% C.I.
0.73, 0.88) at age 10–15 compared to males’ 0.69 (95%
C.I. 0.59, 0.77) at age 10–15, 0.88 (95% C.I. 0.80, 0.93)
compared to 0.73 (95% C.I. 0.62, 0.82) at age 15–20,
0.89 (95% C.I. 0.79, 0.94) compared to 0.76 (95% C.I.
0.59, 0.86) at age 20–25, and 0.92 (95% C.I. 0.83, 0.96)
compared to 0.76 (95% C.I. 0.52, 0.89) at age 25–30, but
none of the other stratification categories showed a large
difference that was sustained across all age categories.
For a full list of stratum-specific concordance correlation
coefficient estimates including gender, race, glomerular
versus non-glomerular disease and height z-score, see
Additional file 3. Figure 3 presents a chart assessing the
ratio between the CKD-EPI and Schwartz equations
among patients at age 18 with patients divided into cat-
egories by Z-score. There is a trend towards a larger ra-
tio (greater disparity) in stunted patients.
Table 2 summarizes the semi-partial R2 estimates for
specific predictors from the overall model with R2 = 0.9
with approximate 95% confidence limits. Age explained
most of the variance, followed by sex, then race, then
height Z-score, and finally followed by type of CKD.
Discussion
Key results
We explored the extent of agreement between the new
Schwartz and the CKD-EPI equations for eGFR estima-
tion in a longitudinal, racially diverse cohort of AYAs
with CKD, with the intent to provide clinical recommen-
dations for the use of these equations in patients with
CKD transitioning into adulthood. We found disagree-
ment between the Schwartz and CKD-EPI equations at
all ages in this CKD cohort. The disagreement was lar-
gest in patients aged 10–15 years old, but there was bet-
ter agreement as patients aged. CKD-EPI consistently
estimated higher GFRs compared to the Schwartz
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measurements across all age groups and observed strata.
In the absence of a gold standard GFR measurement, we
cannot state which formula is better. Disagreement be-
tween the CKD-EPI [8] and Schwartz [7] equations was
lower among female than male patients at every age,
perhaps due to the lower muscle mass or less pro-
nounced stunted growth in women. Our analyses also
exhibited that age and sex are both important compo-
nents of the overall variance between the two renal func-
tion estimating equations, reinforcing that both
attributes play important roles in the relative perform-
ance of the two equations. The use of a sex-specific ad-
justment in CKD-EPI may have contributed to the fact
that the equation performed more comparably to
Schwartz in women than in men, though this bears fur-
ther investigation. Most importantly, the switch from
Schwartz to CKD-EPI eGFR estimation introduced dis-
continuity across our entire analysis due to discordance
between both formulae.
Limitations
We do not have a gold-standard measured GFR and can
thus only assess agreement rather than which formula is
most accurate. However, CKD-EPI and the new
Schwartz [7] eGFR formulae have been well validated in
their respective age groups. Due to the data’s abstraction
Table 1 Population Description and Anthropometric Data
Variable Mean (SD) or n (%) Missing values n
Type of Kidney Disease 0
Glomerular 151 (62)
Non-Glomerular 91 (38)
Stage of Kidney Disease at first height value (by Schwartz) 26a
Stage 1 49 (23)
Stage 2 65 (30)
Stage 3 63 (29)
Stage 4 24 (11)
Stage 5 15 (7)
Gender 0
Male 134 (55)
Female 108 (45)
Race 2
African-American 93 (38)
Non-African American 147 (62)
Age at cohort entry (years) 0
Mean (SD) 14.6 (4.4)
Median (IQR) 13.6 (11.4, 16.3)
Follow-up duration (years) 11b
Mean (SD) 4.5 (3.3)
Median (IQR) 4.0 (1.4, 6.3)
BMI at first possible calculation 9
Z-score if < age 18 (n = 207) 0.91 (1.14)
BMI if > = age 18 (n = 36) 26.1 (6.7)
Height 9
Z-score (at first height) 0.08 (1.27)
Total eGFR measures across all patients 4094
Age 10–15 1702 (41.6)
Age 15–20 1715 (41.9)
Age 20–25 715 (17.5)
Age 25–30 549 (13.4)
aThese patients contributed only to the smoothed population curve for CKDEPI
bGenerally patients contributing 1 measurement to the data set
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from electronic medical health records, there may be
concerns about the accuracy or reliability of these lab
measures. There are also concerns with missing data on
height preventing estimation of GFRs using the Schwartz
equations for some of the patients at some time points,
but we overcame this obstacle by imputing height values
between measurements. While this is a limitation,
growth is pretty linear, and the error due to height
imputation can be considered negligible. Another limita-
tion is due to the higher number of measurements in
the younger age groups (see Table 1).
Interpretation
Overall, our study demonstrates that among AYAs with
CKD, the CKD-EPI and Schwartz equations are discord-
ant during the transition-age period and early adulthood.
Fig. 1 Estimated Glomerular Filtration Rates by Age and Estimating Equation. Legend: These figures describe trends in eGFR over time based
upon the CKD-EPI equation (dashed line) or the Schwartz equation (solid line). Panel a) describes the overall population trajectory, while Panel b)
depicts separate trajectories for males (on the right) and females (on the left)
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Fig. 2 Bland-Altman Plots for Each of Four Age Groups. Legend: These Bland-Altman plots depict the agreement between our two
measurements at each creatinine measurement within age intervals, with each panel from a) to d) representing a separate age group. The closer
the central dashed line representing the mean to 0 within each plot, the better the agreement within that age group
Fig. 3 Ratio in Estimated Glomerular Filtration Rates (CKD-EPI/Schwartz) by Height Category at Age 18. Legend: These box and whiskers plot
illustrate the value of the GFRs estimated by the CKD-EPI equation divided by the GFRs estimated by the Schwartz equation, with the diamonds
representing means, the middle lines representing medians, the edges of the boxes representing quartiles, and the whiskers representing the
range. The closer each value to 1, the more similar the equation estimates are for a given height category
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Selistre et al. [12] examined the difference in accuracy of
the two equations across a broad spectrum of age cat-
egories using cross-sectional broad categories of age (2–
12, 13–17, 18–40, 41–64, > = 65 years-old) but did not
focus on the paediatric-adult transition. In Selistre’s
study, a gold standard GFR measurement was per-
formed, and he concluded that the Schwartz formula
might be more accurate for young adults. Other studies
assessing potential age cut-offs for kidney function equa-
tion [30] switching used measured GFRs for comparison
or formulae incorporating both cystatin C and serum
creatinine [31]. These studies identified similar trends in
agreement as patients aged. A very recent study by Ng et
al. compared creatinine and creatinine and cystatin
C-based eGFR formulae in young adults with the diag-
nosis of paediatric CKD aged 18–26 years of age and
concluded “clinicians should be aware that individually
the paediatric and adult serum creatinine-based esti-
mates of GFR had large discrepancies among emerging
adults with paediatric CKD.” The group recommends
taking the average of paediatric and adult serum
creatinine-based formulae (i.e. the new Schwartz bedside
and the CKD-EPI creatinine only formulae) as a valid
tool for clinical use [32]. Of course, this approach needs
further validation, but the results by Ng et al. are fully
aligned with our findings. The current contribution aug-
ments the findings and suggests that this approach may
be needed until age 30.
Generalizability
The results of this study apply to other nephrology cen-
tres and possibly other diseases where eGFR is an im-
portant biomarker in similar settings within North
America and other populations with a mix of Caucasian,
African American and Hispanic patients. Groups with
different ethnic makeup may have differing agreement
between the two equations, although our study did not
show this.
Conclusion
The new Schwartz and CKD-EPI equations exhibit poor
agreement in AYAs with CKD before and during the
transition period. Concordance rises steadily as AYAs
age but it is certain that differences between equations
remain even after age 18, though these differences were
less dramatic for female patients in our study than for
male patients. Our findings suggest that switching to the
CKD-EPI equation after age 18 may not be an appropriate
method for estimating renal function in AYAs with CKD,
as the discordance between equations will result in abrupt
changes in estimated renal function. Additional studies
with measured GFRs, specifically aiming to estimate renal
function during the transitioning age period and early
adulthood are necessary to understand how to best esti-
mate GFR in AYAs with CKD and track disease progres-
sion across the entire life course of this condition.
Additional files
Additional file 1: Estimated Glomerular Filtration Rate by Each Equation
Overall and for Relevant Subgroups. These figures describe trends in
eGFR over time based upon the CKD-EPI equation (dashed line) or the
Schwartz equation (solid line). Panel A) describes the overall population
trajectory, while Panel B) depicts separate trajectories for each third of
height Z-score. Panel C) depicts separate trajectories for glomerular and
non-glomerular CKD, panel D) shows separate trajectories for males and
females, and panel E) shows separate trajectories for African American
and non-African American participants. (TIF 618 kb)
Additional file 2: Subject Aggregated Bland-Altman Plots by Age Group.
These Bland-Altman plots depict the agreement between our two mea-
surements within age intervals, with each panel from A) to D) represent-
ing a separate age group. The closer the central dashed line representing
the mean to 0 within each plot, the better the agreement within that
age group. Unlike the figure in the main text, each individual can only
contribute one dot to the plot collapsed across all creatinine measure-
ments. (TIF 193 kb)
Additional file 3: Subgroup-specific Concordance Correlation
Coefficients. This table presents subgroup-specific concordance correl-
ation coefficients beyond those described in the text. (DOCX 13 kb)
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